Background Guidelines recommend treatment of latent tuberculosis in patients at increased
risk for active tuberculosis. Studies investigating the association of therapy with serious …

Background An important problem limiting treatment of latent tuberculosis infection is the
occurrence of adverse events with isoniazid. We combined populations from phase 2 and …

SETTING: Latent tuberculous infection (LTBI) remains a significant source of new active
tuberculosis cases. Recent guidelines encourage primary care physicians to prescribe LTBI …

Objective Treatment of latent TB infection (LTBI) in high-risk populations has been identified
as a priority activity for reducing TB incidence. Treatment completion rates are usually far …

Objectives To determine the rate of and risk factors for discontinuation of isoniazid due to
adverse effects during the treatment of latent tuberculosis infection in a large, multi-site …

Clinical trials suggest less hepatotoxicity and better adherence with 4 months rifampin (4R)
versus 9 months isoniazid (9H) for treating latent tuberculosis infection (LTBI). Our objectives …

Background. Despite strong evidence and recommendations supporting the treatment of
latent tuberculosis infection, many affected health care workers at risk of acquiring …

Background Successful treatment of latent tuberculosis infection (LTBI) is essential to reduce
tuberculosis (TB) incidence rates in low-burden countries. This study measures treatment …

Background: Treatment of latent tuberculosis infection with isoniazid for 9 months is
complicated by poor patient adherence and the need for close follow-up of side effects …

Treatment of latent tuberculosis (TB) infection (LTBI) is essential for the elimination of TB in
the United States, but treatment is often not completed. Little is known about patients' …